An April 2020 study showed that a vaccine candidate developed in response to the 2012 Middle East Respiratory Syndrome epidemic was effective in combating MERS in rhesus macaque monkeys, which are genetically similar to humans.
The potential MERS vaccine, ChAdOx1 nCoV-19, is now being tested in human trials in the U.K. and Saudi Arabia to determine whether it might be effective against COVID-19, which is related to the MERS-CoV coronavirus.
The trial has received U.K. government support and drawn the participation of AstraZeneca, a large pharmaceutical company. Researchers involved in the vaccine trials say results are at least six months away.